No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
The pharmacokinetics of testosterone administered either intramuscularly or subcutaneously were evaluated in adolescent transgender men (n=24, age 17-24 years) receiving oral PrEP with emtricitabine/tenofovir-DF. PrEP did not significantly alter testosterone total and free concentrations. AUC and Cmax of total testosterone both decreased by 9% with PrEP; AUC and Cmax of free testosterone decreased by 12% and 11% with PrEP.